The Indian Council of Medical Research (ICMR) has opened its doors to private partners for the joint development and commercialisation of a novel vaccine targeting both typhoid and paratyphoid. This technology, developed at ICMR-National Institute for Research in Bacterial Infections (NIRBI), Kolkata, harnesses outer membrane vesicles derived from Salmonella Typhi, Salmonella Paratyphi, and Salmonella Typhimurium.
India has one of the highest burdens of typhoid worldwide, with an estimated incidence of 360 cases per 100,000 people, translating to millions of annual infections. The new vaccine is anticipated to reduce the disease’s impact by providing comprehensive coverage against multiple strains.
Interested manufacturers will be shortlisted based on research and development capability, infrastructure, and technical plans. Once selected, they will sign a non-disclosure agreement and proceed with further R&D, validation, and marketing, paying a two percent royalty on net sales.
"Such technical oversight by ICMR-NIRBI Institute would accelerate the development of the Product and its commercialisation," said the Council.
ICMR will offer expert support throughout all phases, ensuring adherence to regulatory standards and facilitating a swift product rollout. Doctors across India can anticipate a powerful tool for reducing the prevalence of enteric fever complications.
